Trial Information

Summary: A Phase I Dose Finding Study of TRC105 in Patients with Advanced or Metastatic Solid Cancer

The purpose of this study is to evaluate the safety and tolerability of TRC105 when administered to patients with solid tumors. The study will assess the effects of the drug on patients and their cancers and will look at the pharmacokinetics of TRC105. Pharmacokinetics (PKs) is a way to determine the level of drug in the patient's blood and to study how the body processes the drug by looking at how the the drug is distributed, metabolized and eliminated. This is done by frequent blood draws on key days during the first four weeks of treatment.

TRC105 is a genetically engineered human/murine chimeric monoclonoal antibody directed against human CD105, a growth proliferation receptor. It is a targeted therapy and since it is not approved by the FDA, it is considered investigational in this study.

Patient Inclusion Criteria:

• patients with tumors that are refractory to known therapies or for which no curative therapy is available

Not all eligibility criteria are listed. Additional criteria must be met in order to be eligible.

Patient Exclusion Criteria:

• weight > 120 kg
• BP >160/90
• no lung cancer with central lesions
• no peritoneal carcinomatosis on CT
• no clinical significant pericardial, pleural or peritoneal effusions within 3 months

If you would like to learn more about participating in this study, please send an e-mail message using the form below.